A Phase 2/3 interventional study of ADG20 and Placebo in COVID-19, sponsored by Invivyd, Inc.. Terminated at 95 sites in 9 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-08-20.
Sponsored by Invivyd, Inc. · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,860 studies in COVID-19 with a site in United States, this one is the 97th largest by enrollment of the 1,322 interventional ones that give a count, is one of 504 that started in 2021, is one of 70 in phase 2/3, and was the 1,099th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–75
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,860 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 482 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 504 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,582 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 92 across the 1,322 interventional studies, 300 across the 521 observational. Of the 1,415 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,860 have an industry lead sponsor. The 10 most frequent:
Invivyd, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
Invivyd, Inc. has 9 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
84 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-12 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 84 to your calendar (.ics) → With an account.
Among the 1,860 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This placebo-controlled study is intended to evaluate ADG20's safety and ability to prevent COVID-19 infection.
Phase 2/3, multicenter, double-blind, placebo-controlled, randomized study of the mAb ADG20 in the prevention of symptomatic COVID-19 in adults and adolescents with no known history of SARS-CoV-2 infection but whose circumstances place them at increased risk of acquiring SARS-CoV-2 infection and developing symptomatic COVID-19. This objective was independently evaluated in a cohort of participants with reported recent exposure to an individual diagnosed with a SARS-CoV-2 infection (post-exposure prophylaxis) and in a cohort of participants with no reported exposure to SARS-CoV-2 (pre-exposure prophylaxis). These cohorts included participants whose advanced age (≥55 years old) or health status placed them at risk for severe COVID-19 or COVID-19 complications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Is at high risk of SARS-CoV-2 infection as assessed by the Investigator:
Exclusion Criteria:
NOTE: Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be dosed on Day 1 with ADG20 IM
Drug: ADG20
Participants will be dosed on Day 1 with placebo IM
Drug: Placebo
Single dose of ADG20
Single dose of placebo
Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PEP)
RT-PCR-confirmed symptomatic COVID-19 is determined by a positive central or local (in the absence of central test) RT-PCR test from a nasopharyngeal or saliva sample accompanied by protocol-defined COVID-19 symptoms occurring within 14 days from the sample collection date. Any COVID-19-related hospitalization with a positive local SARS-CoV-2 test (within 14 days) or all-cause death are counted toward the endpoint.
Time frame: Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier
Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PrEP)
RT-PCR-confirmed symptomatic COVID-19 is determined by a positive central or local (in the absence of central test) RT-PCR test from a nasopharyngeal or saliva sample accompanied by protocol-defined COVID-19 symptoms occurring within 14 days from the sample collection date. Any COVID-19-related hospitalization with a positive local SARS-CoV-2 test (within 14 days) or all-cause death are counted toward the endpoint.
Time frame: Day 1 through 3 Months or emergence of Omicron (15-Dec-2021), whichever is earlier
Solicited Injection Site Reactions (PEP, PrEP)
Percentage of participants with at least one solicited injection site reaction
Time frame: Day 1 through Day 4
Participants With at Least 1 Treatment Emergent Adverse Events (PEP, PrEP)
Any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment; includes solicited injection site reactions
Time frame: Day 1 through 14 Months or 25Jul2022, whichever is earlier
Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PEP)
RT-PCR-confirmed symptomatic COVID-19 is determined by a positive central or local (in the absence of central test) RT-PCRtest from a nasopharyngeal or saliva sample accompanied by protocol-defined COVID-19 symptoms occurring within 14 days from the sample collection date. Any COVID-19-related hospitalization with a positive local SARS-CoV-2 test (within 14 days) or all-cause death are counted toward the endpoint.
Time frame: Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier
Percentage of Participants With SARS-CoV-2 Infection (Asymptomatic or Symptomatic) as Determined by Positive RT-PCR or Serology (PEP)
Participants with RT-PCR-confirmed symptomatic COVID-19 (protocol defined COVID-19 symptoms occurring within 14 days from the sample collection date of a positive central or local \[in the absence of central test\] RT-PCR, any COVID-19-related hospitalization with a positive local SARS-CoV-2 test \[within 14 days\], or all-cause death), central RT-PCR-confirmed SARS-CoV-2 infection, or central serology-confirmed SARS-CoV-2 infection with negative central serology at baseline.
Time frame: Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier
Percentage of Participants With Asymptomatic SARS-CoV-2 Infection as Determined by RT-PCR (PEP)
Defined as having a central RT-qPCR-confirmed SARS-CoV-2 infection without having an RT-PCR-confirmed symptomatic COVID-19 outcome
Time frame: Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier
Percentage of Participants With Asymptomatic SARS-CoV-2 Infection as Determined by Serology (PEP)
Defined as having a central serology-confirmed SARS-CoV-2 infection (with a negative central serology test sample at baseline) and without having an RT-PCR-confirmed symptomatic COVID-19 outcome (including COVID-19-related hospitalization and all-cause death)
Time frame: Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier
Percentage of Participants With Asymptomatic SARS-CoV-2 Infection as Determined by Serology (PrEP)
Defined as having a central serology-confirmed SARS-CoV-2 infection (with a negative central serology test sample at baseline) and without having an RT-PCR-confirmed symptomatic COVID-19 outcome (including COVID-19-related hospitalization and all-cause death)
Time frame: Day 1 through 6 Months or emergence of Omicron (15-Dec-2021), whichever is earlier
SARS-CoV-2 Viral Load as Assessed by RT-qPCR Change From Baseline in Asymptomatic Participants (PEP)
Asymptomatic SARS-CoV-2 infection confirmed by RT-qPCR from nasal swab collected at Day 8 and Day 15. Viral load values reported as detected but below the lower quantification of the PCR assay (\< 714 copies/mL) are imputed with half the lower limit of quantification of the PCR assay (i.e., 357 copies/mL = 2.55 log10 copies/mL). Viral load values reported as \> 7.1×10\^7 copies/mL are imputed with 7.1×10\^7 copies/mL (i.e., 7.85 log10 copies/mL).
Time frame: Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier
Percentage of Participants With RT-PCR Confirmed Mild, Moderate, or Severe/Critical COVID-19 (PEP)
Maximum severity assessed from COVID-19-like illness (CLI) Day 1 through CLI Day 28. COVID-19-related hospitalizations or COVID-19-related deaths from CLI Day 1 to CLI Day 28 are categorized as severe/critical.
Time frame: Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier
Percentage of Participants With RT-PCR Confirmed Mild, Moderate, or Severe/Critical COVID-19 (PrEP)
Maximum severity assessed from COVID-19-like Illness (CLI) Day 1 through CLI Day 28. COVID-19-related hospitalizations or COVID-19-related deaths from CLI Day 1 to CLI Day 28 are categorized as severe/critical.
Time frame: Day 1 through 3 Months or emergence of Omicron (15-Dec-2021), whichever is earlier
Percentage of Participants With at Least 1 COVID-19 Related Medically Attended Outpatient Visit (PEP)
Physician office, telemedicine, emergency room or urgent care center visits in participants with RT-PCR-confirmed symptomatic COVID-19 events, defined as having a central RT-PCR-confirmed SARS-CoV-2 infection with COVID-19 symptoms occurring within 14 days from the positive RT-PCR test sample collection, COVID-19-related hospitalization with a positive local or central SARS-CoV-2 test within 14 days, or all-cause death.
Time frame: Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier
Percentage of Participants With at Least 1 COVID-19 Related Medically Attended Outpatient Visit (PrEP)
Physician office, telemedicine, emergency room or urgent care center visits in participants with RT-PCR confirmed symptomatic COVID-19, defined as having a central RT-PCR-confirmed SARS-CoV-2 infection with COVID-19 symptoms occurring within 14 days from the positive RT-PCR test sample collection, COVID-19-related hospitalization with a positive local or central SARS-CoV-2 test within 14 days, or all-cause death.
Time frame: Day 1 through 3 Months or emergence of Omicron (15-Dec-2021), whichever is earlier
Percentage of Participants With a COVID-19 Related Hospitalization (PEP)
Time frame: Through 28 Days from COVID-19-like illness initial visit (CLI Day 1)
Percentage of Participants With a COVID-19 Related Hospitalization (PrEP)
Time frame: Through 28 days from COVID-19-like illness initial visit (CLI Day 1)
COVID-19 Related Mortality (PEP)
Time frame: Through 28 Days from COVID-19-like illness initial visit (CLI Day 1)
COVID-19 Related Mortality (PrEP)
Time frame: Through 28 Days from COVID-19-like illness initial visit (CLI Day 1)
All-Cause Mortality (PEP)
Time frame: Through 28 Days from COVID-19-like illness initial visit (CLI Day 1)
All-Cause Mortality (PrEP)
Time frame: Through 28 Days from COVID-19-like illness initial visit (CLI Day 1)
Viral Load as Assessed by RT-qPCR in Participants With Confirmed Symptomatic COVID-19 (PEP)
Viral load from COVID-19-like illness (CLI) Day 1 sample. Viral load values reported as detected but below the lower quantification of the PCR assay (\< 714 copies/mL) are imputed with half the lower limit of quantification of the PCR assay (i.e., 357 copies/mL = 2.55 log10 copies/mL). Viral load values reported as \> 7.1×10\^7 copies/mL are imputed with 7.1×10\^7 copies/mL (i.e., 7.85 log10 copies/mL).
Time frame: Positive CLI Day 1 sample through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier
Viral Load as Assessed by RT-qPCR in Participants With Confirmed Symptomatic COVID-19 (PrEP)
Viral load from COVID-19-like Illness (CLI) Day 1 sample. Viral load values reported as detected but below the lower quantification of the PCR assay (\< 714 copies/mL) are imputed with half the lower limit of quantification of the PCR assay (i.e., 357 copies/mL = 2.55 log10 copies/mL). Viral load values reported as \> 7.1×10\^7 copies/mL are imputed with 7.1×10\^7 copies/mL (i.e., 7.85 log10 copies/mL).
Time frame: Positive CLI Day 1 sample through 3 Months or emergence of Omicron (15-Dec-2021), whichever is earlier
Assessment of PK Parameter: ADG20 Plasma Concentrations (PEP)
PK samples collected at protocol-defined timepoints
Time frame: Day 1 through 12 Months or end of study (11-Jan-2022), whichever is earlier
Assessment of PK Parameter: ADG20 Plasma Concentrations (PrEP)
PK samples collected at protocol-defined timepoints
Time frame: Day 1 through 12 Months or end of study (11-Jan-2022), whichever is earlier
Time From Randomization to First RT-PCR-confirmed Symptomatic COVID-19 (PEP)
Outcome measure is presented as cumulative probability expressed in percentage. RT-PCR-confirmed symptomatic COVID-19 event is defined as having a central RT-PCR-confirmed SARS-CoV-2 infection with COVID-19 symptoms occurring within 14 days from the positive RT-PCR test sample collection, COVID-19-related hospitalization with a positive local or central SARS-CoV-2 test within 14 days, or all-cause death.
Time frame: An average of 2 months up to 7 months through cutoff date prior to emergence of Omicron (15-Dec-2021)
Time From Randomization to First RT-PCR-confirmed Symptomatic COVID-19 (PrEP)
Outcome measure is presented as cumulative probability expressed in percentage. RT-PCR-confirmed symptomatic COVID-19 event is defined as having a central RT-PCR-confirmed SARS-CoV-2 infection with COVID-19 symptoms occurring within 14 days from the positive RT-PCR test sample collection, COVID-19-related hospitalization with a positive local or central SARS-CoV-2 test within 14 days, or all-cause death.
Time frame: An average of 2.5 months up to 7.5 months through cutoff date prior to emergence of Omicron (15-Dec-2021)
| Milestone | ADG20 IM - Cohort A | Placebo IM - Cohort A | ADG20 IM - Cohort B | Placebo IM - Cohort B |
|---|---|---|---|---|
| Started | 245 | 242 | 1048 | 1047 |
| Completed | 32 | 35 | 226 | 236 |
| Not completed | 213 | 207 | 822 | 811 |
RT-PCR-confirmed symptomatic COVID-19 is determined by a positive central or local (in the absence of central test) RT-PCR test from a nasopharyngeal or saliva sample accompanied by protocol-defined COVID-19 symptoms occurring within 14 days from the sample collection date. Any COVID-19-related hospitalization with a positive local SARS-CoV-2 test (within 14 days) or all-cause death are counted toward the endpoint.
| Participants | ADG20 IM - Cohort A | Placebo IM - Cohort A |
|---|---|---|
| Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PEP) | 3 | 12 |
RT-PCR-confirmed symptomatic COVID-19 is determined by a positive central or local (in the absence of central test) RT-PCR test from a nasopharyngeal or saliva sample accompanied by protocol-defined COVID-19 symptoms occurring within 14 days from the sample collection date. Any COVID-19-related hospitalization with a positive local SARS-CoV-2 test (within 14 days) or all-cause death are counted toward the endpoint.
| Participants | ADG20 IM - Cohort B | Placebo IM - Cohort B |
|---|---|---|
| Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PrEP) | 12 | 40 |
Percentage of participants with at least one solicited injection site reaction
| Participants | ADG20 IM - Cohort A | Placebo IM - Cohort A | ADG20 IM - Cohort B | Placebo IM - Cohort B |
|---|---|---|---|---|
| Solicited Injection Site Reactions (PEP, PrEP) | 12 | 7 | 75 | 73 |
Any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment; includes solicited injection site reactions
| Participants | ADG20 IM - Cohort A | Placebo IM - Cohort A | ADG20 IM - Cohort B | Placebo IM - Cohort B |
|---|---|---|---|---|
| Participants With at Least 1 Treatment Emergent Adverse Events (PEP, PrEP) | 42 | 51 | 399 | 362 |
RT-PCR-confirmed symptomatic COVID-19 is determined by a positive central or local (in the absence of central test) RT-PCRtest from a nasopharyngeal or saliva sample accompanied by protocol-defined COVID-19 symptoms occurring within 14 days from the sample collection date. Any COVID-19-related hospitalization with a positive local SARS-CoV-2 test (within 14 days) or all-cause death are counted toward the endpoint.
| Participants | ADG20 IM - Cohort A | Placebo IM - Cohort A |
|---|---|---|
| Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PEP) | 1 | 7 |
Participants with RT-PCR-confirmed symptomatic COVID-19 (protocol defined COVID-19 symptoms occurring within 14 days from the sample collection date of a positive central or local \[in the absence of central test\] RT-PCR, any COVID-19-related hospitalization with a positive local SARS-CoV-2 test \[within 14 days\], or all-cause death), central RT-PCR-confirmed SARS-CoV-2 infection, or central serology-confirmed SARS-CoV-2 infection with negative central serology at baseline.
| Participants | ADG20 IM - Cohort A | Placebo IM - Cohort A |
|---|---|---|
| Percentage of Participants With SARS-CoV-2 Infection (Asymptomatic or Symptomatic) as Determined by Positive RT-PCR or Serology (PEP) | 6 | 14 |
Defined as having a central RT-qPCR-confirmed SARS-CoV-2 infection without having an RT-PCR-confirmed symptomatic COVID-19 outcome
| Participants | ADG20 IM - Cohort A | Placebo IM - Cohort A |
|---|---|---|
| Percentage of Participants With Asymptomatic SARS-CoV-2 Infection as Determined by RT-PCR (PEP) | 3 | 1 |
Defined as having a central serology-confirmed SARS-CoV-2 infection (with a negative central serology test sample at baseline) and without having an RT-PCR-confirmed symptomatic COVID-19 outcome (including COVID-19-related hospitalization and all-cause death)
| Participants | ADG20 IM - Cohort A | Placebo IM - Cohort A |
|---|---|---|
| Percentage of Participants With Asymptomatic SARS-CoV-2 Infection as Determined by Serology (PEP) | 0 | 1 |
Defined as having a central serology-confirmed SARS-CoV-2 infection (with a negative central serology test sample at baseline) and without having an RT-PCR-confirmed symptomatic COVID-19 outcome (including COVID-19-related hospitalization and all-cause death)
| Participants | ADG20 IM - Cohort B | Placebo IM - Cohort B |
|---|---|---|
| Percentage of Participants With Asymptomatic SARS-CoV-2 Infection as Determined by Serology (PrEP) | 10 | 18 |
Asymptomatic SARS-CoV-2 infection confirmed by RT-qPCR from nasal swab collected at Day 8 and Day 15. Viral load values reported as detected but below the lower quantification of the PCR assay (\< 714 copies/mL) are imputed with half the lower limit of quantification of the PCR assay (i.e., 357 copies/mL = 2.55 log10 copies/mL). Viral load values reported as \> 7.1×10\^7 copies/mL are imputed with 7.1×10\^7 copies/mL (i.e., 7.85 log10 copies/mL).
| Viral load (log10 copies/mL) | ADG20 IM - Cohort A | Placebo IM - Cohort A |
|---|---|---|
| Day 8 | 2.96 ± 4.186 | 0 ± 0 |
| Day 15 | 2.15 ± 1.985 | 3.16 |
Maximum severity assessed from COVID-19-like illness (CLI) Day 1 through CLI Day 28. COVID-19-related hospitalizations or COVID-19-related deaths from CLI Day 1 to CLI Day 28 are categorized as severe/critical.
| Participants | ADG20 IM - Cohort A | Placebo IM - Cohort A |
|---|---|---|
| Cohort A (PEP) Mild | 3 | 7 |
| Cohort A (PEP) Moderate | 0 | 2 |
| Cohort A (PEP) Severe/Critical | 0 | 3 |
Maximum severity assessed from COVID-19-like Illness (CLI) Day 1 through CLI Day 28. COVID-19-related hospitalizations or COVID-19-related deaths from CLI Day 1 to CLI Day 28 are categorized as severe/critical.
| Participants | ADG20 IM - Cohort B | Placebo IM - Cohort B |
|---|---|---|
| Cohort B (PrEP) Mild | 7 | 14 |
| Cohort B (PrEP) Moderate | 4 | 19 |
| Cohort B (PrEP) Severe/Critical | 1 | 7 |
Physician office, telemedicine, emergency room or urgent care center visits in participants with RT-PCR-confirmed symptomatic COVID-19 events, defined as having a central RT-PCR-confirmed SARS-CoV-2 infection with COVID-19 symptoms occurring within 14 days from the positive RT-PCR test sample collection, COVID-19-related hospitalization with a positive local or central SARS-CoV-2 test within 14 days, or all-cause death.
| Participants | ADG20 IM - Cohort A | Placebo IM - Cohort A |
|---|---|---|
| Percentage of Participants With at Least 1 COVID-19 Related Medically Attended Outpatient Visit (PEP) | 0 | 3 |
Physician office, telemedicine, emergency room or urgent care center visits in participants with RT-PCR confirmed symptomatic COVID-19, defined as having a central RT-PCR-confirmed SARS-CoV-2 infection with COVID-19 symptoms occurring within 14 days from the positive RT-PCR test sample collection, COVID-19-related hospitalization with a positive local or central SARS-CoV-2 test within 14 days, or all-cause death.
| Participants | ADG20 IM - Cohort B | Placebo IM - Cohort B |
|---|---|---|
| Percentage of Participants With at Least 1 COVID-19 Related Medically Attended Outpatient Visit (PrEP) | 1 | 6 |
| Participants | ADG20 IM - Cohort A | Placebo IM - Cohort A |
|---|---|---|
| Percentage of Participants With a COVID-19 Related Hospitalization (PEP) | 0 | 3 |
| Participants | ADG20 IM - Cohort B | Placebo IM - Cohort B |
|---|---|---|
| Percentage of Participants With a COVID-19 Related Hospitalization (PrEP) | 1 | 6 |
| Participants | ADG20 IM - Cohort A | Placebo IM - Cohort A |
|---|---|---|
| COVID-19 Related Mortality (PEP) | 0 | 0 |
| Participants | ADG20 IM - Cohort B | Placebo IM - Cohort B |
|---|---|---|
| COVID-19 Related Mortality (PrEP) | 0 | 1 |
| Participants | ADG20 IM - Cohort A | Placebo IM - Cohort A |
|---|---|---|
| All-Cause Mortality (PEP) | 0 | 0 |
| Participants | ADG20 IM - Cohort B | Placebo IM - Cohort B |
|---|---|---|
| All-Cause Mortality (PrEP) | 0 | 1 |
Viral load from COVID-19-like illness (CLI) Day 1 sample. Viral load values reported as detected but below the lower quantification of the PCR assay (\< 714 copies/mL) are imputed with half the lower limit of quantification of the PCR assay (i.e., 357 copies/mL = 2.55 log10 copies/mL). Viral load values reported as \> 7.1×10\^7 copies/mL are imputed with 7.1×10\^7 copies/mL (i.e., 7.85 log10 copies/mL).
| log10 copies/mL | ADG20 IM - Cohort A | Placebo IM - Cohort A |
|---|---|---|
| Viral Load as Assessed by RT-qPCR in Participants With Confirmed Symptomatic COVID-19 (PEP) | 2.43 ± 2.372 | 5.74 ± 2.689 |
Viral load from COVID-19-like Illness (CLI) Day 1 sample. Viral load values reported as detected but below the lower quantification of the PCR assay (\< 714 copies/mL) are imputed with half the lower limit of quantification of the PCR assay (i.e., 357 copies/mL = 2.55 log10 copies/mL). Viral load values reported as \> 7.1×10\^7 copies/mL are imputed with 7.1×10\^7 copies/mL (i.e., 7.85 log10 copies/mL).
| Log10 copies/mL | ADG20 IM - Cohort B | Placebo IM - Cohort B |
|---|---|---|
| Viral Load as Assessed by RT-qPCR in Participants With Confirmed Symptomatic COVID-19 (PrEP) | 4.58 ± 2.730 | 6.58 ± 1.825 |
PK samples collected at protocol-defined timepoints
| ug/mL | ADG20 IM - Cohort A |
|---|---|
| Day 8 | 36.3 ± 15.4 |
| Day 28 | 33.6 ± 12.6 |
PK samples collected at protocol-defined timepoints
| ug/mL | ADG20 IM - Cohort B |
|---|---|
| Day 8 | 38.2 ± 14.7 |
| Day 28 | 33.6 ± 12.5 |
Outcome measure is presented as cumulative probability expressed in percentage. RT-PCR-confirmed symptomatic COVID-19 event is defined as having a central RT-PCR-confirmed SARS-CoV-2 infection with COVID-19 symptoms occurring within 14 days from the positive RT-PCR test sample collection, COVID-19-related hospitalization with a positive local or central SARS-CoV-2 test within 14 days, or all-cause death.
| Percent probability | ADG20 IM - Cohort A | Placebo IM - Cohort A |
|---|---|---|
| Day 28 | 1.74 | 7.01 |
| Day 60 | 1.74 | 7.84 |
| Day 90 | 1.74 | 7.84 |
Outcome measure is presented as cumulative probability expressed in percentage. RT-PCR-confirmed symptomatic COVID-19 event is defined as having a central RT-PCR-confirmed SARS-CoV-2 infection with COVID-19 symptoms occurring within 14 days from the positive RT-PCR test sample collection, COVID-19-related hospitalization with a positive local or central SARS-CoV-2 test within 14 days, or all-cause death.
| Percent probability | ADG20 IM - Cohort B | Placebo IM - Cohort B |
|---|---|---|
| Day 28 | 0.96 | 2.32 |
| Day 60 | 1.31 | 5.64 |
| Day 90 | 2.01 | 7.26 |
Collected over Baseline through Month 14 or end of study (11-Jan-2022), whichever is earlier. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ADG20 IM - Cohort A | 0/240 (0%) | 4/240 (1.7%) | 0/240 (0%) |
| Placebo IM - Cohort A | 2/241 (0.8%) | 8/241 (3.3%) | 0/241 (0%) |
| ADG20 IM - Cohort B | 3/1,001 (0.3%) | 46/1,001 (4.6%) | 126/1,001 (12.6%) |
| Placebo IM - Cohort B | 6/1,001 (0.6%) | 46/1,001 (4.6%) | 123/1,001 (12.3%) |
| Event | ADG20 IM - Cohort A | Placebo IM - Cohort A | ADG20 IM - Cohort B | Placebo IM - Cohort B |
|---|---|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 1/240 | 4/241 | 1/1001 | 9/1001 |
| COVID-19Infections and infestations | 0/240 | 0/241 | 3/1001 | 6/1001 |
| PneumoniaInfections and infestations | 1/240 | 0/241 | 4/1001 | 2/1001 |
| Abortion spontaneous incompletePregnancy, puerperium and perinatal conditions | 1/240 | 0/241 | 0/1001 | 0/1001 |
| GoutMetabolism and nutrition disorders | 1/240 | 0/241 | 0/1001 | 0/1001 |
| InfluenzaInfections and infestations | 0/240 | 1/241 | 0/1001 | 0/1001 |
| Toxicity to various agentsInjury, poisoning and procedural complications | 0/240 | 1/241 | 0/1001 | 1/1001 |
| Gun shot woundInjury, poisoning and procedural complications | 0/240 | 1/241 | 1/1001 | 1/1001 |
| ContusionInjury, poisoning and procedural complications | 0/240 | 1/241 | 0/1001 | 0/1001 |
| Hip fractureInjury, poisoning and procedural complications | 0/240 | 0/241 | 0/1001 | 2/1001 |
| Event | ADG20 IM - Cohort A | Placebo IM - Cohort A | ADG20 IM - Cohort B | Placebo IM - Cohort B |
|---|---|---|---|---|
| Injection site painGeneral disorders | — | — | 76/1001 | 84/1001 |
| Influenza like illnessGeneral disorders | — | — | 59/1001 | 46/1001 |
| Age, Categorical(Participants) | ADG20 IM - Cohort A | Placebo IM - Cohort A | ADG20 IM - Cohort B | Placebo IM - Cohort B | Total |
|---|---|---|---|---|---|
| <=18 years | 5 | 2 | 7 | 2 | 16 |
| Between 18 and 65 years | 209 | 220 | 942 | 923 | 2294 |
| >=65 years | 31 | 20 | 99 | 122 | 272 |
| Age, Continuous(years) | ADG20 IM - Cohort A | Placebo IM - Cohort A | ADG20 IM - Cohort B | Placebo IM - Cohort B | Total |
|---|---|---|---|---|---|
| Mean | 45.4 ± 15.61 | 45.4 ± 14.52 | 46.5 ± 13.90 | 47.1 ± 14.10 | 46.8 ± 14.00 |
| Sex: Female, Male(Participants) | ADG20 IM - Cohort A | Placebo IM - Cohort A | ADG20 IM - Cohort B | Placebo IM - Cohort B | Total |
|---|---|---|---|---|---|
| Female | 123 | 120 | 508 | 522 | 1273 |
| Male | 122 | 122 | 540 | 525 | 1309 |
| Ethnicity (NIH/OMB)(Participants) | ADG20 IM - Cohort A | Placebo IM - Cohort A | ADG20 IM - Cohort B | Placebo IM - Cohort B | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 146 | 143 | 217 | 248 | 754 |
| Not Hispanic or Latino | 99 | 99 | 785 | 751 | 1734 |
| Unknown or Not Reported | 0 | 0 | 46 | 48 | 94 |
| Race (NIH/OMB)(Participants) | ADG20 IM - Cohort A | Placebo IM - Cohort A | ADG20 IM - Cohort B | Placebo IM - Cohort B | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 5 | 12 | 17 |
| Asian | 0 | 0 | 10 | 8 | 18 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 6 | 6 | 13 |
| Black or African American | 29 | 30 | 168 | 182 | 409 |
| White | 214 | 210 | 821 | 803 | 2048 |
| More than one race | 0 | 1 | 15 | 11 | 27 |
| Unknown or Not Reported | 1 | 1 | 23 | 25 | 50 |
| Region of Enrollment(participants) | ADG20 IM - Cohort A | Placebo IM - Cohort A | ADG20 IM - Cohort B | Placebo IM - Cohort B | Total |
|---|---|---|---|---|---|
| Argentina | 0 | 1 | 6 | 7 | 14 |
| Romania | 43 | 36 | 0 | 0 | 79 |
| United States | 180 | 180 | 870 | 868 | 2098 |
| Czechia | 0 | 0 | 3 | 5 | 8 |
| Ukraine | 22 | 25 | 82 | 81 | 210 |
| Poland | 0 | 0 | 17 | 16 | 33 |
| Moldova | 0 | 0 | 5 | 2 | 7 |
| Georgia | 0 | 0 | 65 | 68 | 133 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2021 to primary completion in Nov 2022, 18 months.
Results were first posted in Aug 2024, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Invivyd, Inc.